NewsBenzingaArdent Health aumenta la guidance dell’EPS GAAP per l’esercizio 2026 da $0,78-$1,15 a $0,93-$1,18, rispetto a $0,95 stimato; conferma la guidance dei ricavi per l’esercizio 2026 di $6,400 miliardi-$6,700 miliardi, rispetto a $6,463 miliardi stimati Ardent Health aumenta la guidance dell’EPS GAAP per l’esercizio 2026 da $0,78-$1,15 a $0,93-$1,18, rispetto a $0,95 stimato; conferma la guidance dei ricavi per l’esercizio 2026 di $6,400 miliardi-$6,700 miliardi, rispetto a $6,463 miliardi stimati Benzinga 2026.11.04 21:58 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3